Literature DB >> 16556024

The dynamic roles of angiopoietins in tumor angiogenesis.

Qin Yu1.   

Abstract

Angiopoietin (Ang)-1 and -2, and mouse Ang-3/human Ang-4 are ligands of the receptor tyrosine kinase with immunoglobulin and epidermal growth factor homology domains (Tie)-2. It is well established that the Ang-Tie-2 pathway is involved in tumor angiogenesis. However, the exact effects of angiopoietins on tumor angiogenesis are under debate. Experimental and clinical studies have demonstrated that increased expression of Ang-1 and -2 promotes or inhibits tumor angiogenesis, and correlates with a reduced or extended survival time of patients, and with a declined or improved clinical outcome. In general, these studies suggest that Ang-1 is a proangiogenic factor that promotes endothelial cell survival and tumor angiogenesis, especially in the presence of vascular endothelial growth factor; whereas Ang-2 destabilizes vasculature that leads to the initiation of angiogenesis or apoptosis of endothelial cells/vessel regression in the presence or absence of vascular endothelial growth factor, respectively, and that the cell-surface tethered Ang-3 displays antiangiogenic activity. Together, these results suggest that the Ang-Tie-2 functional axis is an attractive target for antiangiogenesis-based cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16556024     DOI: 10.2217/14796694.1.4.475

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  7 in total

1.  Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.

Authors:  Angela Coxon; James Bready; Hosung Min; Stephen Kaufman; Juan Leal; Dongyin Yu; Tani Ann Lee; Ji-Rong Sun; Juan Estrada; Brad Bolon; James McCabe; Ling Wang; Karen Rex; Sean Caenepeel; Paul Hughes; David Cordover; Haejin Kim; Seog Joon Han; Mark L Michaels; Eric Hsu; Grant Shimamoto; Russell Cattley; Eunju Hurh; Linh Nguyen; Shao Xiong Wang; Anthony Ndifor; Isaac J Hayward; Beverly L Falcón; Donald M McDonald; Luke Li; Tom Boone; Richard Kendall; Robert Radinsky; Jonathan D Oliner
Journal:  Mol Cancer Ther       Date:  2010-10       Impact factor: 6.261

2.  Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis.

Authors:  Melissa K Brunckhorst; Hui Wang; Rong Lu; Qin Yu
Journal:  Cancer Res       Date:  2010-09-07       Impact factor: 12.701

3.  Angiogenic gene characterization and vessel permeability of dermal microvascular endothelial cells isolated from burn hypertrophic scar.

Authors:  Esteban A Molina; Brandon Hartmann; Mary A Oliver; Liam D Kirkpatrick; John W Keyloun; Lauren T Moffatt; Jeffrey W Shupp; Taryn E Travis; Bonnie C Carney
Journal:  Sci Rep       Date:  2022-07-18       Impact factor: 4.996

4.  Design, Cytotoxicity and Antiproliferative Activity of 4-Amino-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylates against MFC-7 and MDA-MB-231 Breast Cancer Cell Lines.

Authors:  Anelia Mavrova; Stephan Dimov; Inna Sulikovska; Denitsa Yancheva; Ivan Iliev; Iana Tsoneva; Galya Staneva; Biliana Nikolova
Journal:  Molecules       Date:  2022-05-21       Impact factor: 4.927

5.  Matrix metalloproteinase-1 and thrombin differentially activate gene expression in endothelial cells via PAR-1 and promote angiogenesis.

Authors:  Jessica S Blackburn; Constance E Brinckerhoff
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

6.  Pocket2Drug: An Encoder-Decoder Deep Neural Network for the Target-Based Drug Design.

Authors:  Wentao Shi; Manali Singha; Gopal Srivastava; Limeng Pu; J Ramanujam; Michal Brylinski
Journal:  Front Pharmacol       Date:  2022-03-11       Impact factor: 5.810

7.  LeadOp+R: Structure-Based Lead Optimization With Synthetic Accessibility.

Authors:  Fang-Yu Lin; Emilio Xavier Esposito; Yufeng J Tseng
Journal:  Front Pharmacol       Date:  2018-03-05       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.